Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 34Carcinoma, Hepatocellular 33Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Lung Neoplasms 9Rectal Neoplasms 8Nasopharyngeal Carcinoma 8Esophageal Neoplasms 6Cholangiocarcinoma 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Carcinoma 3Breast Neoplasms 3Spinocerebellar Degenerations 2Sarcoma 2Recurrence 2Nonsquamous Non-Small Cell Lung Cancer 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Locally Advanced Rectal Cancer 2

Interventions

Gemcitabine 26Capecitabine 16Oxaliplatin 14Fluorouracil 13Cisplatin 12Leucovorin 9pembrolizumab 5Erlotinib Hydrochloride 5Bevacizumab 5durvalumab 4Trastuzumab 4Specimen Handling 4Sorafenib 4Magnetic Resonance Spectroscopy 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3Lapatinib 3Irinotecan 3Carboplatin 3Biopsy 3tremelimumab 2toripalimab 2regorafenib 2lenvatinib 2dehydroftorafur 2cobimetinib 2atezolizumab 2anlotinib 2Nivolumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × sintilimab × Clear all
NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Fudan University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡